finance

finance

Iterum resubmits NDA for new uUTI antibiotic

DUBLIN - Iterum Therapeutics plc (NASDAQ:), a clinical-stage pharmaceutical company, announced today the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral antibiotic sulopenem etzadroxil/probenecid, intended for the treatment of uncomplicated...

This website uses cookies. By continuing to use this site, you accept our use of cookies.